This company has been marked as potentially delisted and may not be actively trading. Poseida Therapeutics (PSTX) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock PSTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged CompanyJuly 23, 2025 | globenewswire.comRoche Finalizes Poseida Acquisition: This Cell Therapy Deal Feels Like A Win/WinJanuary 9, 2025 | seekingalpha.comRoche set to finalise $1.5bn Poseida Therapeutics takeoverJanuary 8, 2025 | proactiveinvestors.comRoche to complete acquisition of U.S. biopharma company PoseidaJanuary 8, 2025 | reuters.comPoseida Therapeutics (NASDAQ:PSTX) Reaches New 1-Year High - Here's What HappenedJanuary 7, 2025 | marketbeat.comPoseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Purchased by Barclays PLCJanuary 5, 2025 | marketbeat.comPoseida Therapeutics (NASDAQ:PSTX) Sees Strong Trading Volume - What's Next?January 2, 2025 | marketbeat.comPoseida Therapeutics (NASDAQ:PSTX) Sets New 1-Year High - Here's WhyDecember 31, 2024 | marketbeat.comPoseida Therapeutics, Inc. (NASDAQ:PSTX) Stock Position Lowered by Wellington Management Group LLPDecember 20, 2024 | marketbeat.comXTX Topco Ltd Has $523,000 Stock Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX)December 14, 2024 | marketbeat.comMark J. Gergen Sells 30,000 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) StockDecember 12, 2024 | insidertrades.comCautious Hold Rating on Poseida Therapeutics Amid Promising Data and Strategic UncertaintiesDecember 10, 2024 | markets.businessinsider.comPoseida Therapeutics (NASDAQ:PSTX) Reaches New 12-Month High - Here's WhyDecember 10, 2024 | marketbeat.comPoseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual MeetingDecember 9, 2024 | prnewswire.comJacobs Levy Equity Management Inc. Trims Stock Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX)December 8, 2024 | marketbeat.comPoseida Therapeutics downgraded to Neutral from Overweight at Piper SandlerDecember 2, 2024 | markets.businessinsider.comRoche’s Acquisition Offer Leads to Hold Rating for Poseida Therapeutics Amid Promising Pipeline and Financial UncertaintiesDecember 2, 2024 | markets.businessinsider.comThe Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and NovartisDecember 2, 2024 | uk.finance.yahoo.comFred Alger Management LLC Buys Shares of 128,970 Poseida Therapeutics, Inc. (NASDAQ:PSTX)December 2, 2024 | marketbeat.comPoseida Therapeutics, Inc. (NASDAQ:PSTX) Chairman Sells $278,100.00 in StockNovember 28, 2024 | insidertrades.comConnor Clark & Lunn Investment Management Ltd. Grows Stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX)November 28, 2024 | marketbeat.comPOSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida ...November 28, 2024 | businesswire.comPOSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTXNovember 27, 2024 | businesswire.comBTIG Downgrades Poseida Therapeutics (PSTX)November 27, 2024 | msn.comWilliam Blair downgrades Poseida Therapeutics (PSTX) to a HoldNovember 27, 2024 | markets.businessinsider.comPoseida Therapeutics (PSTX) was downgraded to a Hold Rating at BTIGNovember 27, 2024 | markets.businessinsider.comAdvantage Alpha Capital Partners LP Invests $285,000 in Poseida Therapeutics, Inc. (NASDAQ:PSTX)November 27, 2024 | marketbeat.comPoseida Therapeutics (NASDAQ:PSTX) Lowered to "Hold" Rating by Cantor FitzgeraldNovember 27, 2024 | marketbeat.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc. - PSTXNovember 26, 2024 | prnewswire.comWhy This Gene-Therapy Company's Stock Is Rising 228%November 26, 2024 | barrons.comRoche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 BillionNovember 26, 2024 | msn.comShareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public ShareholdersNovember 26, 2024 | businesswire.comHC Wainwright Reiterates "Neutral" Rating for Poseida Therapeutics (NASDAQ:PSTX)November 26, 2024 | marketbeat.comPSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to ShareholdersNovember 26, 2024 | businesswire.comRoche to acquire US-based Poseida TherapeuticsNovember 26, 2024 | reuters.comPoseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.November 26, 2024 | prnewswire.comPoseida Therapeutics: Promising Advancements and Strategic Collaborations Drive Buy RatingNovember 15, 2024 | markets.businessinsider.comWhere Poseida Therapeutics Stands With AnalystsNovember 15, 2024 | benzinga.comPoseida Therapeutics (PSTX) Receives a Buy from Piper SandlerNovember 15, 2024 | markets.businessinsider.comPoseida Therapeutics (NASDAQ:PSTX) Earns "Buy" Rating from HC WainwrightNovember 15, 2024 | marketbeat.comPoseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical PipelineNovember 14, 2024 | prnewswire.comPoseida Therapeutics to Present at Two Upcoming Investor ConferencesNovember 11, 2024 | prnewswire.comPoseida Therapeutics holds virtual R&D DayNovember 9, 2024 | markets.businessinsider.comPoseida Therapeutics Reports Strong Q3 2024 ProgressNovember 9, 2024 | markets.businessinsider.comPoseida Therapeutics' (PSTX) Buy Rating Reiterated at HC WainwrightNovember 8, 2024 | marketbeat.comPoseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024November 7, 2024 | prnewswire.comPoseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024November 5, 2024 | prnewswire.comBuy Recommendation for Poseida Therapeutics: Harnessing Allogeneic CAR-T Technology for Autoimmune DiseasesOctober 31, 2024 | markets.businessinsider.comPoseida Therapeutics (NASDAQ:PSTX) Given Buy Rating at HC WainwrightOctober 30, 2024 | marketbeat.comPoseida Therapeutics to present data on P-KLKB1-101 in hereditary angioedemaOctober 24, 2024 | markets.businessinsider.com Get Poseida Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address PSTX Media Mentions By Week PSTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTX News Sentiment▼0.001.04▲Average Medical News Sentiment PSTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTX Articles This Week▼01▲PSTX Articles Average Week Get Poseida Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SRRK News Today SWTX News Today PTGX News Today AAPG News Today MLTX News Today HCM News Today ALVO News Today IMVT News Today MOR News Today KYMR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTX) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThe Fed Just Froze You Out (Again)The Fed’s holding rates steady—again. No clarity. No yield. No relief. But one income strategy is quietly t...Investors Alley | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredSomething BIG is about to hit the stock marketMost investors won’t see it coming—but Weiss Ratings says a major market event is brewing. Their system jus...Weiss Ratings | SponsoredThe $1 Trillion Event Tesla Still Hasn’t Recovered FromIn 2010, a “Flash Crash” erased $1 trillion in minutes. Now, one trading legend says it’s happening again—insi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poseida Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Poseida Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
